New drug combo shows promise for rare blood disorder
NCT ID NCT01623167
First seen Apr 23, 2026 · Last updated May 03, 2026 · Updated 2 times
Summary
This study tests whether adding eltrombopag to standard immune-suppressing drugs can help people with severe aplastic anemia, a rare condition where the immune system attacks the bone marrow. About 207 untreated patients aged 2 and older will receive the combination and be monitored for improved blood cell counts. The goal is to see if this approach is safe and more effective than standard treatment alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.